XML 31 R25.htm IDEA: XBRL DOCUMENT
v3.25.3

Earnings Per Share | 9 Months Ended
--- | ---
Sep. 30, 2025
Earnings Per Share [Abstract] |
Earnings Per Share | Note 14. Earnings per share Basic and diluted net income (loss) per share attributable to common stockholders is computed in accordance with Note 2. Basis of presentation, summary of significant accounting policies and recent accounting pronouncements – Net income (loss) per share attributable to common stockholders. The following table presents potentially dilutive securities that were not included in the computation of diluted net (loss) income per share of common stock as their inclusion would have been anti-dilutive and or their issuance upon satisfying a contingency, if applicable, was not satisfied or deemed satisfied as of period end:
|  | Three Months Ended |  |  | Nine Months Ended |
|  | September 30, |  |  | September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Akerna Common Warrants |  |  | 21,739 |  |  |  | - |  |  |  | 21,739 |  |  |  | — |
Akerna Underwriter Warrants |  |  | 1,087 |  |  |  | - |  |  |  | 1,087 |  |  |  | — |
Gryphon Warrants |  |  | 108,587 |  |  |  | - |  |  |  | 108,587 |  |  |  | — |
Total |  |  | 131,413 |  |  |  | - |  |  |  | 131,413 |  |  |  | — |
The following is a reconciliation of the denominator of the basic and diluted net income (loss) per share of common stock computations for the periods presented:
|  | Three Months Ended |  |  | Nine Months Ended |
|  | September 30, |  |  | September 30, |
(in USD thousands, except share and per share amounts) |  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Numerator: |  |  |  |  |  |  |  |  |  |  |  |
Net income (loss) |  | $ | 3,475 |  |  | $ | (576 | ) |  | $ | (93,717 | ) |  | $ | 168,773 |
Less: loss from discontinued operations (net of income tax benefit of nil, nil, nil, and $1.6 million, respectively) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 4,816 |
Net income from continuing operations – basic |  | $ | 3,475 |  |  | $ | (576 | ) |  | $ | (93,717 | ) |  | $ | 173,589 |
Effect of dilutive shares on net income: |  |  |  |  |  |  |  |  |  |  |  |
Gryphon warrants revaluation included in net income (loss) (net of income tax benefit) (1) |  |  | (19 | ) |  |  | — |  |  |  | — |  |  |  | — |
Net income from continuing operations – diluted |  | $ | 3,456 |  |  | $ | (576 | ) |  | $ | (93,717 | ) |  | $ | 173,589 |
Loss from discontinued operations (net of income tax benefit of nil, nil, nil and $1.6 million, respectively) |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | (4,816 | )
Denominator: |  |  |  |  |  |  |  |  |  |  |  |
Weighted average shares of common stock outstanding – basic |  |  | 899,354,931 |  |  |  | 891,762,280 |  |  |  | 894,366,300 |  |  |  | 891,762,280 |
Dilutive impact of Gryphon Warrants |  |  | 134,495 |  |  |  | — |  |  |  | — |  |  |  | — |
Weighted average shares of common stock outstanding – diluted |  |  | 899,489,426 |  |  |  | 891,762,280 |  |  |  | 894,366,300 |  |  |  | 891,762,280 |
Net income (loss) per share of common stock: |  |  |  |  |  |  |  |  |  |  |  |
Basic from continuing operations (2) |  | $ | — |  |  | $ | — |  |  | $ | (0.10 | ) |  | $ | 0.19 |
Basic from discontinued operations (3) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (0.01 | )
Diluted from continuing operations (4) |  | $ | — |  |  | $ | — |  |  | $ | (0.10 | ) |  | $ | 0.19 |
Diluted from discontinued operations (5) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (0.01 | )
(1) Calculated as the net adjustment from warrant liability fair value remeasurement from Gryphon Warrants, net of tax (2) Calculated as net income from continuing operations – basic, divided by weighted average shares of common stock outstanding – basic (3) Calculated as loss from discontinued operations divided by weighted average shares of common stock outstanding – basic (4) Calculated as net income from continuing operations – diluted, divided by weighted average shares of common stock outstanding – diluted (5) Calculated as loss from discontinued operations divided by weighted average shares of common stock outstanding – diluted

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration